How do weight loss injections affect hormone levels in PCOS?

GLP-1 receptor agonists (such as liraglutide and semaglutide) can improve some hormonal features of PCOS, largely by supporting weight loss and improving metabolic health. Clinical studies show modest reductions in androgen markers (including total testosterone and, in some studies, the free androgen index) and may improve menstrual frequency or regularity in some women. Evidence that GLP-1 therapy consistently improves insulin resistance measures is mixed, and reproductive outcomes are not reported uniformly across trials.

Key points:

GLP-1 therapies in PCOS are associated with modest reductions in total testosterone.
Some studies report improvements in the free androgen index and other reproductive markers, though findings vary.
Evidence for improved insulin sensitivity is inconsistent across studies.
Menstrual frequency and cycle regularity may improve in some women.
Benefits often lessen after stopping treatment, particularly if weight is regained.

This text has been fact-checked for accuracy by Sorin Romaniuc, Pharmacist at medino.